Pub-2024

Articles

Title
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom’s Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom’s Macroglobulinemia
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom’s Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom’s Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom’s Macroglobulinemia on the management of patients with high-risk disease
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom’s Macroglobulinemia related neuropathy
ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia